We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bladder Cancer Cell Receptor Detectable in Urine and Prostatic Fluid

By Labmedica staff writers
Posted on 17 Mar 2008
A new cell receptor was found on cancerous cells in patients suffering from bladder cancer. More...
When the receptor sloughs off the cancer cells, it can be found in urine and prostatic fluid (in men). The first of its kind, the cell receptor offers great potential as a non-invasive, easy-to-make dipstick or rapid urine test that could transform the screening and diagnosis process for bladder cancer

The receptor was discovered by scientists at the Medical University of South Carolina for Research and Development (MUSC; Charleston, SC, USA). Current tests for bladder cancer are accurate for only 40% of diagnoses. MUSC's new test has demonstrated 90% accuracy (100% specificity) in human urine samples of patients with various degrees of bladder cancer, confirming the newly discovered cell receptor's efficacy in diagnosing that cancer.

Patients undergo bladder cancer screening if they are determined to have certain risk factors including a previous diagnosis of bladder cancer, birth defects of the bladder, advanced age (over 55), or work-related exposure to certain chemicals. Bladder cancer affects men more than women, as well as whites more than other ethnicities, according to the American Cancer Society. The organization estimates that of the approximately 69,000 new bladder cancer cases in the United States this year, almost 52,000 will be in men.

Current studies report that patients with successfully treated bladder cancer still have a 50-80% recurrence rate, making this potential urine-based test perfect for home cancer recurrence monitoring. For the methods most routinely used to detect or monitor bladder cancer, convenience, comfort, and pain are issues important to patients. The new diagnostic test from MUSC could eliminate the need for invasive tests such as cystoscopy and biopsies that can be painful and even cause medical complications.


Related Links:
Medical University of South Carolina for Research and Development

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.